Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Why are prions and amyloid structures immune suppressive and other intriguing questions facing neuroimmunologists in the future.
Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis.
Acute demyelinating encephalomyelitis presenting with psychiatric symptoms.
Neuroprotective Effects of Endurance Exercise against High Fat Diet-Induced Hippocampal Neuroinflammation.
Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Molecular basis of axonal dysfunction and traffic impairments in CMT.
Treatment Satisfaction With Disease Modifying Therapies In Multiple Sclerosis: A Systematic Review of Studies Using The Treatment Satisfaction Questionnaire For Medication (Tsqm).
Ranking of Disease-Modifying Therapies for Multiple Sclerosis.
Arctigenin Suppress Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis Through AMPK and PPAR-γ/ROR-γt Signaling.
Mechanistic Perspectives of Maslinic Acid in Targeting Inflammation.
Validation of Social Media Analysis for Outcomes Research: Identification of Drivers of Switches between oral and Injectable Therapies for Multiple Sclerosis.
Mechanostimulation Promotes Nuclear and Epigenetic Changes in Oligodendrocytes.
The astrocyte in multiple sclerosis revisited.
Adherence Associated with Oral Medications in the Treatment of Spasticity.
[Need for creating Polish registry of multiple sclerosis patients].
Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases.
Whom to Target for Falls-Prevention Trials: Recommendations from the International MS Falls Prevention Research Network.
The polarity protein scribble regulates myelination and remyelination in the central nervous system.
Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.
Assessment of Dysmyelination with RAFFn MRI: Application to Murine MPS I.
Neuropsychiatric side-effects of interferon-alpha treatment: pathophysiology and therapeutic options.
[Vitamin d, determinant of bone and extrabone health . Import ance of vitamin d supplementation in milk and dairy products].
The diagnostic value of MRI in pediatric chronic inflammatory demyelinating polyradiculoneuropathy.
Functional adaptation of presynaptic chemokine receptors in EAE mouse central nervous system.
IgE-mediated hypersensitivity reaction and desensitization to glatiramer acetate in a pediatric patient.
Pages
« first
‹ previous
…
640
641
642
643
644
645
646
647
648
…
next ›
last »